| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," "we" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP) patients.
Lipella's Phase 2a trial is a multicenter, dose-ranging study involving adult male and female subjects experiencing symptomatic Oral Lichen Planus, a chronic inflammatory condition that affects mucous membranes in the mouth and causes burning and pain as well as white patches, swollen tissue or open sores. OLP affects about 6 million Americans and currently has no FDA-approved therapies.
LP-310 is a novel liposomal-tacrolimus oral rinse based on the company's lead candidate LP-10, which is also being evaluated for hemorrhagic cystitis. This study is expected to conclude in mid-2025. Lipella Pharmaceuticals anticipates reporting top-line data from the study by the end of 2024.
Posted In: LIPO
